Table 3.
SARS-CoV-2 Vaccines.
| Vaccine | Manufacturer/Country | Type | Antigen | Dose/Dosage | Efficacy | Overall Efficacy | Approved Countries | References |
|---|---|---|---|---|---|---|---|---|
| mRNA-1273/SpikeVax | Moderna (US) | mRNA | Full-length spike (S) protein with proline substitutions | 100 μg: 2 doses (28 days apart) | 100% 14 days after second dose | 92.1% 14 days after first dose; 94.1% 14 days after second dose | EUA: the US, EU, Canada, and UK | [57,58,59,60] |
| BNT162b2/Comirnaty | Pfizer.BioNTech (US) | mRNA | Full-length S protein with proline substitutions | 30 μg: 2 doses (21 days apart) | 88.9% after 1 dose | 52% after first dose; 94.6% 7 days after second dose | EUA: the US, EU, Canada, and UK | [61] |
| Ad26.CoV2.S | Janssen/Johnson & Johnson (US) | Viral vector | Recombinant, replication incompetent human adenovirus serotype 26 vector encoding a full-length, stabilized SARS-CoV-2 S protein | 5 × 1010 viral particles: 1 dose | 85% after 28 days; 100% after 49 days | 72% in the US; 66% in Latin America; 57% in South Africa (at 28 days) | EUA: the US, EU, and Canada | [57] |
| ChAdOx1(AZS1222)/ Covishield |
AstraZeneca/Oxford (UK) | Viral vector | Replication-deficient chimpanzee adenoviral vector with the SARS-CoV-2 S protein | 5 × 1010 viral particles: 2 doses (28 days apart) | 100% 21 days after first dose | 64.1% after first dose; 70.4% 14 days after second dose | EUA: WHO/Covax, the UK, India, and Mexico | [57] |
| NVX-CoV2373/Nuvaxovid | Novavax, Inc (US) | Protein subunit | Recombinant full-length, prefusion S protein | 5 μg of protein and 50 μg of Matrix-M adjuvant: 2 doses | Unknown | 89.3% in the UK (after 2 doses); 60% in South Africa | EUA application planned | [62] |
| CVnCov | CureVa/GlaxoSmithKline (Germany) | mRNA | Prefusion stabilized full-length S protein of the SARS-CoV-2 virus | 12 μg: 2 doses (28 days apart) | Unknown | Ongoing Phase 3 trial | Not applicable | [62] |
| Gam-COVID-Vac (Sputnik V) | Gamaleya National Research Center for Epidemiology and Microbiology (Russia) | Viral vector | Full-length SARS-CoV-2 virus glycoprotein S carried by adenoviral vectors | 1011 virus particles per dose for each recombinant adenovirus: 2 doses (first rAd26; second rAd5) (21 days apart) | 100% 21 days after first dose | 87.6% 14 days after first dose; 91.1% 7 days after second dose | EUA: Russia, Belarus, Argentina, Serbia, UAE, Algeria, Palestine, and Egypt | [63] |
| CoronaVac | Sinovac Biotech (China) | Inactivated virus | Inactivated CN02 Strain of SARS-CoV-2 created from Vero cells | 3 μg with aluminum hydroxide adjuvant: 2 doses (14 days apart) | Unknown | Phase 3 data not published; reported efficacy 14 days after dose 2: 50.38% (mild) and 78% (mild to severe) in Brazil, 65% in Indonesia, and 91.25% in Turkey | EUA: China, Brazil, Columbia, Bolivia, Brazil, Chile, Uruguay, Turkey, Indonesia and Azerbaijan | [62] |
| BBIBP-CorV | Sinopharm (China) | Inactivated virus | Inactivated HB02 strain of SARS-CoV-2 created from Vero cells | 4 μg with aluminum hydroxide adjuvant: 2 doses (21 days apart) | Unknown | Phase 3 data not published; unpublished reported 79% and 86% efficacy | EUA: China, UAE, Bahrain, Serbia, Peru, and Zimbabwe | [57] |
| BBV152 | Covaxin (Bharat Biotech, India) | Inactivated virus | Whole SARS-CoV-2 Virion (Strain: NIV-2020-770), inactivated Vero Cell | 6 μg of whole-virion with aluminum hydroxide adjuvant: 2 doses (28 days apart) | 78% after second dose | 77.8% (symptomatic); 93.4% (severe); 63.6% (asymptomatic) | Asia, Europe, Africa, South America, North America, Oceania (Australia) | [64] |
| Ad5-nCoV-S recombinant (Ad5-nCoV) | CanSinoBio/Convidecia | Viral vector | Replication-defective adenovirus type 5 vector expressing the SARS-CoV-2 S protein | 0.5 × 1011 virus particles per dose for each recombinant adenovirus: 1 dose | 90.07% (severe) 28 days after single dose and 95.47% (severe) 14 days after single dose. | 65.28% (symptomatic) 28 days after single dose vaccination, and 68.83% (symptomatic) 14 days after single dose. | Asia, Europe, and Latin America | [64] |